Baminercept

BIOLOGICAL3 trials

Sponsors

University of Zurich, Biogen, National Institute of Allergy and Infectious Diseases (NIAID)

Conditions

Chronic HCV Hepatitis CPrimary Sjögren's SyndromeSecondary Progressive Multiple Sclerosis

Phase 1

A Phase 1b, Single Center, Clinical Study to Investigate the Safety and Biological Responses to Baminercept in Patients With Chronic HCV Hepatitis.

University of ZurichChronic HCV Hepatitis C

Start: 2010-10-31End: 2013-02-28Updated: 2010-07-16

Dose Escalation Study to Evaluate the Penetration and Pharmacodynamic Effects of Baminercept in the Cerebrospinal Fluid (CSF)and Safety in Subjects With Secondary Progressive Multiple Sclerosis (SPMS)

WithdrawnNCT01181089

BiogenSecondary Progressive Multiple Sclerosis

Start: 2010-09-30Updated: 2013-09-16

Phase 2

Baminercept, a Lymphotoxin-Beta Receptor Fusion Protein, for Treatment of Sjögren's Syndrome

TerminatedNCT01552681

National Institute of Allergy and Infectious Diseases (NIAID)Primary Sjögren's Syndrome

Start: 2012-07-31End: 2015-06-30Updated: 2019-01-14

Related Papers

Identification of Novel CD4+ T Cell Subsets in the Target Tissue of Sjögren’s Syndrome and Their Differential Regulation by the Lymphotoxin/LIGHT Signaling Axis

The Journal of Immunology2016-10-0827 citations